Bevarest 400mg Injection (Bevacizumab)

The Bevarest 400mg Injection contains bevacizumab, a monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A). By neutralizing VEGF-A, it suppresses tumor angiogenesis—the formation of new blood vessels that tumors use for oxygen and nutrients. Bevacizumab 400mg Injection is used with chemotherapy or other systemic therapy in multiple cancers, including colorectal, nonsquamous NSCLC, renal, ovarian/fallopian/peritoneal, and cervical cancers, with indication details varying by jurisdiction. The 400 mg/16 mL vial is a supply presentation; patient dosing is weight-based in mg/kg.

Bevacizumab 400mg Injection is used in metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, selected advanced nonsquamous NSCLC regimens, metastatic renal cell carcinoma in selected combinations, recurrent glioblastoma under some labels, epithelial ovarian/fallopian-tube/primary-peritoneal cancer, and persistent/recurrent/metastatic cervical cancer. It is not used as a general anticancer agent for every tumor. Histology matters—serious pulmonary hemorrhage risk is one reason it is avoided in squamous NSCLC. Surgical timing, bleeding risk, uncontrolled hypertension, proteinuria, and GI perforation risk must be assessed before treatment.

Bevacizumab 400mg Injection binds circulating VEGF-A and prevents activation of VEGFR-1/VEGFR-2 on endothelial cells, reducing new-vessel growth and vascular permeability.

AVF2107g: Adding bevacizumab 400mg injection to irinotecan/5-FU/leucovorin improved survival in metastatic colorectal cancer.

ECOG 4599: Bevacizumab 400mg plus carboplatin/paclitaxel improved outcomes in selected nonsquamous NSCLC patients.

GOG-0218 / ICON7: Bevacizumab-containing strategies improved progression-free outcomes in ovarian cancer populations.

A Bevarest 400mg injection can sometimes cause unexpected physical reactions as the body adjusts to the treatment. It is always best to discuss potential responses with a doctor.

Common side effects

• High blood pressure
  
• Protein in urine
  
• Nosebleeds
  
• Headache
  
• Fatigue
  
• Diarrhea
  

Serious side effects

• Gastrointestinal perforation/fistula
  
• Severe hemorrhage
  
• Arterial thromboembolism
  
• Hypertensive crisis/PRES
  
• Nephrotic syndrome
  
• Impaired wound healing
  
• Infusion reactions
  

Important: Dose and regimen must be prescribed by the treating specialist. Tablet/vial strength is not necessarily the patient dose. Do not start, stop, split, combine, or substitute treatment based on website information.

If an infusion is missed, contact the oncology unit. Do not double or shorten the interval independently. The next dose may depend on blood pressure, proteinuria, surgery, bleeding, or toxicity.

• Blood pressure every cycle
  
• Urine protein
  
• Bleeding/thrombosis symptoms
  
• Wound healing/surgical dates
  
• Neurologic symptoms suggestive of PRES
  
• Infusion reactions
  

• Current bevacizumab 400mg Injection prescribing information (Avastin/reference). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125085s340lbl.pdf​
  
• Hurwitz H, et al. AVF2107g. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/15175435/​
  
• Sandler A, et al. ECOG 4599. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/17167137/​
  
• G, joseph et al. Science Direct. Bevacizumab in cancer treatment. https://www.sciencedirect.com/science/article/pii/S0305737220300554​
  
• J.pang, et al. NaturesCommunication. Efficacy of bevacizumab in cancer patients. https://www.nature.com/articles/s41467-021-21085-8​